Authors: Green, CA Fenn, DS Moussaoui, D Kadri, N Hoffman, WF

Citation: Ca. Green et al., Quality of life in treated and never-treated schizophrenic patients, ACT PSYC SC, 103(2), 2001, pp. 131-142

Authors: Duggan, ME Duong, LT Fisher, JE Hamill, TG Hoffman, WF Huff, JR Ihle, NC Leu, CT Nagy, RM Perkins, JJ Rodan, SB Wesolowski, G Whitman, DB Zartman, AE Rodan, GA Hartman, GD

Citation: Me. Duggan et al., Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist, J MED CHEM, 43(20), 2000, pp. 3736-3745

Authors: Hartman, GD Duggan, ME Hoffman, WF Meissner, RJ Perkins, JJ Zartman, AE Naylor-Olsen, AM Cook, JJ Glass, JD Lynch, RJ Zhang, GX Gould, RJ

Citation: Gd. Hartman et al., Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors., BIOORG MED, 9(6), 1999, pp. 863-868

Authors: Ganzini, L Johnston, WS Hoffman, WF

Citation: L. Ganzini et al., Correlates of suffering in amyotrophic lateral sclerosis, NEUROLOGY, 52(7), 1999, pp. 1434-1440